Compare SVC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVC | IMMP |
|---|---|---|
| Founded | 1995 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.4M | 410.7M |
| IPO Year | 1995 | 2012 |
| Metric | SVC | IMMP |
|---|---|---|
| Price | $2.27 | $2.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.6M | 150.3K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ 26.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,814,838,000.00 | N/A |
| Revenue This Year | N/A | $372.23 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.55 | $1.32 |
| 52 Week High | $3.08 | $3.53 |
| Indicator | SVC | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 43.35 |
| Support Level | $2.22 | $2.56 |
| Resistance Level | $2.43 | $2.71 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 53.52 | 11.59 |
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its hotel investment unit and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza Hotels & Resorts, and Hyatt Place.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.